Abstract: A filter-drying device having a compressed-air connector and at least one filter connector, wherein the filter-drying device is adapted to fluidically connect the compressed-air connector to the at least one filter connector in a first functional state and to fluidically separate it from the at least one filter connector in a second functional state, wherein the at least one filter connection is adapted to receive a filter, in particular a multi-usable ventilating filter, and to form an airtight connection between the filter-drying device and the filter.

Abstract: The invention relates to a coupling device with at least one first connector, at least one second connector, at least one third connector and a valve device, wherein the at least one first connector is adapted to fluidically connect a media supply filter test device to the coupling device, wherein the at least one second connector is adapted to fluidically connect a multiplier device to the coupling device, wherein the at least one third connector is configured as a hot steam connector, wherein the at least one first connector, the at least one second connector and the at least one third connector are flow connected to the valve device, wherein the valve device is adapted to connect, in a first operating mode, at least one third connector of the at least one third connector fluidically simultaneously to at least one first connector of the at least one first connector and to at least one second connector of the at least one second connector, so that the media supply filter test device connected to the coupl

Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer.

Abstract: A fastening arrangement fastens a sample holder to a force measuring device. The fastening arrangement has a sample holder, a counterpart holder on the side of the force measuring device. The counterpart holder has a sample holder receptable. The sample holder has a planar abutment surface and the sample holder receptacle has a flat counterpart abutment surface. The sample holder has a positioning element and a fixing element. The sample holder receptacle has a counterpart positioning element and a counterpart fixing element. The positioning element and the counterpart positioning element uniquely define a relative position between the sample holder and the counterpart holder together with the abutment surface and the counterpart abutment surface. The fixing element and the counterpart fixing element hold the sample holder and the counterpart holder against one another and force the abutment surface and the counterpart abutment surface against one another.

Abstract: The invention relates to a fastening assembly (3) for fastening a test device holder (5) to a force measuring apparatus (1), having a test device holder (5) and a slide part (7) which can be or is arranged on a force measurement tower (9) of the force measuring apparatus (1) in such a way that the slide part can move in the vertical direction of the force measurement tower (9). The test device holder (5) has at least one position defining element (11), and the slide part (7) has at least one counter position defining element (13).

Abstract: The invention relates to a force measuring arrangement (3) in particular for applying a test parameter to a specimen and/or for measuring a resistance force applied by the specimen, having at least one force absorption element (25), a first fastening device and a force transmission element (27), wherein the force absorption element (25) can be fastened to a force measuring device in a movable manner by means of the first fastening device, wherein the force absorption element (25) is designed to measure a relative force acting between two force absorption regions, namely a first force absorption region and a second force absorption region (51), wherein the first fastening device is able to be connected to the force absorption element (25) in a force-transmitting manner via the first force absorption region, wherein the second force absorption region (51) is able to be connected to the force transmission element (27) in a force-transmitting manner by means of a second fastening device, wherein the force transmi

Abstract: The present invention relates to a method of purifying whole HCV particles, the method comprising the steps of a) providing a cell culture supernatant comprising virus particles, b) purification and/or concentration of the cell culture supernatant, c) purification and/or concentration of the product of above step b) using steric exclusion chromatography (SXC) at alkaline pH in the range of 8-10, d) purification and/or concentration of the product of above step c) using sulphated cellulose membrane absorbers (SCMA), e) obtaining purified whole virus particles.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane, and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer.

Abstract: The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

Abstract: The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention.

Abstract: The present invention relates to a transdermal therapeutic system formed from (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, in which the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer; a kit containing two transdermal therapeutic systems of the present invention; and methods for the preparation of the transdermal therapeutic system of the present invention. The present invention further relates to methods of treatment based upon the application of the inventive transdermal therapeutic systems once or twice weekly via systems adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

Abstract: The invention relates to a force measuring arrangement (3) in particular for applying a test parameter to a specimen and/or for measuring a resistance force applied by the specimen, having at least one force absorption element (25), a first fastening device and a force transmission element (27), wherein the force absorption element (25) can be fastened to a force measuring device in a movable manner by means of the first fastening device, wherein the force absorption element (25) is designed to measure a relative force acting between two force absorption regions, namely a first force absorption region and a second force absorption region (51), wherein the first fastening device is able to be connected to the force absorption element (25) in a force-transmitting manner via the first force absorption region, wherein the second force absorption region (51) is able to be connected to the force transmission element (27) in a force-transmitting manner by means of a second fastening device, wherein the force transmi

Abstract: The invention relates to a fastening arrangement (3) for fastening a sample holder (7) to a force measuring device (1), having a sample holder (7), and a counterpart holder (5) on the side of the force measuring device, which is formed or arranged on the force measuring device (1) or is fixedly connectable to the force measuring device (1), wherein the counterpart holder (5) has at least one sample holder receptacle (19, 21), wherein the sample holder (7) has a planar abutment surface (39) and the sample holder receptacle (19, 21) has a flat counterpart abutment surface (23), wherein the sample holder (7) furthermore has at least one positioning element (41, 43) and one fixing element (45), and the sample holder receptacle (19, 21) has at least one counterpart positioning element (25, 27) and one counterpart fixing element (29), wherein the positioning element (41, 43) and the counterpart positioning element (25, 27) are configured to uniquely define a relative position between the sample holder (7) and th

Abstract: The invention relates to a fastening assembly (3) for fastening a test device holder (5) to a force measuring apparatus (1), having a test device holder (5) and a slide part (7) which can be or is arranged on a force measurement tower (9) of the force measuring apparatus (1) in such a way that the slide part can move in the vertical direction of the force measurement tower (9). The test device holder (5) has at least one position defining element (11), and the slide part (7) has at least one counter position defining element (13).

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a nom-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: A system can include a memory to store machine readable instructions. The system can also include a processing unit to access the memory and execute the machine readable instructions. The machine readable instructions can include a scheduling agent that can determine a download time for selected media content from a content provider. The download time can be based on a viewing time and a monitored network usage pattern over an extended period of time at the system.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane,and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.